Preventing graft versus host disease in children with blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 0 and 25 years old
- You must have a blood cancer that needs a stem cell transplant from a half-matched donor
- You must be in fairly good overall health (performance score over 70%)
- Your heart must be working well enough (ejection fraction at least 40%)
- You cannot have active hepatitis, HIV, or a life-threatening infection
- You must agree to be followed for 3 years after the transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Hear when a new Acute Myeloid Leukemia, Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.